Accuray (ARAY)
Accuray (ARAY) Stock Price, Analysis & Data
| Bid | 0.25 |
| Market Cap | 34.98M |
| Revenue (ttm) | 428.57M |
| Net Income (ttm) | -46.13M |
| Beta | 1.39 |
| EPS (ttm) | -0.38 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.22 |
| P/B (ttm) | 0.83 |
| P/S (ttm) | 0.08 |
| Earnings Date | Oct 29, 2020 |
| Ask | 0.34 |
| Volume | 115,152 |
| Avg. Volume (20D) | 3,384,082 |
| Open | 0.28 |
| Previous Close | 0.28 |
| Day's Range | 0.28 - 0.30 |
| 52-Week Range | 0.22 - 2.10 |
| Analyst | n/a |
| Price Target | 0.35 (20.69%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ARAY
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and...
Financial Performance
In 2025, Accuray's revenue was 458.5M, an increase of 2.68% compared to the previous year's 446.55M. Earnings were -1.59M, a decrease of -89.77%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for ARAY stock is "null". The 12-month stock price forecast is 0.35, which is upside of 20.69% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade